Daily Pill Daraxonrasib Shows Major Promise in Early Trials for Advanced Pancreatic Cancer

Early trial results show that the targeted therapy daraxonrasib, combined with chemotherapy, halted tumour growth in 90% of patients with advanced pancreatic cancer and made tumours undetectable on scans in roughly 8% of participants.

A daily pill called daraxonrasib, used alongside chemotherapy, has shown significant promise in early medical trials for treating advanced pancreatic cancer. In a phase I/II trial involving 61 participants recently diagnosed with advanced pancreatic cancer that had spread to other parts of the body, tumours stopped growing in 90% of patients. Just over 60% saw their tumours shrink or disappear, and in one in 12 patients—approximately 8%—cancer became undetectable on CT scans. Editorial illustration

Daraxonrasib is a targeted inhibitor treatment already approved in the United States. It works by shutting off RAS mutations found in most pancreatic cancers. Experts from Memorial Sloan Kettering Cancer Center and Cancer Research UK have described the findings as a major breakthrough. Cancer Research UK called the results "the biggest leap forward in decades" for pancreatic cancer patients. The research was presented at the EORTC–NCI–AACR Symposium.

Despite the encouraging data, doctors caution that the treatment is not yet a cure. Longer studies are needed to determine the duration of remission and assess the potential for significantly improved overall survival and time before tumour regrowth. There is also interest in whether the treatment could be applied to other cancers with similar RAS mutations, such as lung and ovarian cancer. Editorial illustration

Pancreatic cancer has the lowest survival rate of common cancers in the UK. In Britain, there are 11,500 diagnoses of pancreatic cancer each year and around 10,200 deaths. In the United States, the disease accounts for about 3% of all cancers and 8% of all cancer deaths, killing around 53,000 people a year.

Sources